Therapy News and Research

RSS

MaxCyte appoints Ali Soleymannezhad as Chief Commercial Officer

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer, effective as of September 11, 2024.

From MaxCyte, Inc. 11 Oct 2024

Mount Sinai launches new center for complex chronic illnesses

Mount Sinai's Department of Rehabilitation and Human Performance has announced the grand opening of the Cohen Center for Recovery From Complex Chronic Illnesses (CoRE), providing clinical care for patients with conditions such as long Lyme disease/Lyme+, long COVID, and other infection-associated complex chronic illnesses such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Ehlers-Danlos syndrome (EDS).

10 Oct 2024

Specialized in-bed cycling therapy reduces ICU stay for critically ill patients

A new systematic review led by researchers in Hamilton, Canada has shown that specialized in-bed cycling therapy, when used in the intensive care unit with critically ill patients, leads to better physical function and a one-day shorter length of stay in the ICU.

10 Oct 2024

Understanding why some children develop PTSD and anxiety after trauma

A new study has shed light on why some children and adolescents develop mental health disorders like PTSD, anxiety, or depression after experiencing a traumatic event.

10 Oct 2024

New magnetogenetics technology holds promise as a powerful tool for studying the brain

A new technology enables the control of specific brain circuits non-invasively with magnetic fields, according to a preclinical study from researchers at Weill Cornell Medicine, The Rockefeller University and the Icahn School of Medicine at Mount Sinai.

10 Oct 2024

Study reveals how bacterial selfishness affects antibiotic resistance strategies

As strains of pathogens resistant to frontline antibiotics become more common worldwide, clinicians are more often turning to combination treatments that degrade this resistance as a first treatment option.

10 Oct 2024

MSU researchers test new nanotherapy infusion to target arterial inflammation

Inflammation of the arteries is a primary precursor and driver of cardiovascular disease - the No. 1 killer of people in the United States. This inflammation is associated with the buildup of dangerous plaque inside the arteries.

10 Oct 2024

Grant supports gene-editing research for rare metabolic diseases

A $14M grant will fund research on gene-editing therapies for rare metabolic diseases at the Perelman School of Medicine at the University of Pennsylvania (Penn) and Children's Hospital of Philadelphia (CHOP).

10 Oct 2024

Older men’s connections often wither when they’re on their own

At age 66, South Carolina physician Paul Rousseau decided to retire after tending for decades to the suffering of people who were seriously ill or dying. It was a difficult and emotionally fraught transition.

10 Oct 2024

Understanding the long-term effects of subtle abuse

New research from the University of East Anglia has uncovered a significant gap in understanding of a harmful form of domestic abuse known as subtle or covert abuse.

10 Oct 2024

Could heparin offer new hope in the fight against dementia?

Heparin therapy delays Alzheimer's diagnosis by one to two years, offering potential insights into new protective treatments. Large-scale health records show a promising association between the anticoagulant and delayed dementia onset.

10 Oct 2024

Study illuminates the origin and progression of bladder cancer

How bladder cancer originates and progresses has been illuminated as never before in a study led by researchers at Weill Cornell Medicine and the New York Genome Center.

9 Oct 2024

Novel gene therapy holds potential in treating patients with epilepsy

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) are working on a therapy that holds potential in treating patients with epilepsy, a neurological disorder defined by recurring seizures due to abnormal brain activity.

9 Oct 2024